小智港股覆盤 | 8月5日
今日，港股三大指數集體上漲。截止收盤，恆生指數漲0.14%，報20201點。國企指數漲0.33%，報6902點。恆生科技指數漲0.79%，報4415點。市場約1028只個股上漲，595只個股下跌。成交額突破851.7億港幣，和昨天同期相比下跌4.24%。南下資金淨流入4.38億港幣。
盤面上，海運板塊全線走強。亞洲能源物流漲超22%；東方海外國際漲超7%；潤利海事、太平洋航運等多股漲超4%；海豐國際漲超2%。部分港口航運股走強，東方海外國際漲3.74%。
醫療服務板塊表現強勁。中國衛生集團漲超22%；百濟神州漲超11%；科濟藥業-B漲超10%；藥明巨諾-B漲超9%；信達生物、康方生物-B等多股漲超8%；智雲健康漲超6%；清晰醫療漲超5%；中國生物科技服務漲超4%；諾輝健康-B漲超3%。中國衛生集團特別股東大會通過“10 合 1”股份合併；百濟神州BTK百悅澤上半年全球收入2.331億美元，在美銷售額同比增長5倍；藥明巨諾－Ｂ漲11.13%；信達生物曾續漲11%，溢價發新股引資賽諾菲；交銀推薦買入康方生物及榮昌生物(09995）持續看好中國創新藥研發；中國生物科技服務發盈喜，預期中期取得公司擁有人應佔溢利淨額不少於6500萬港元，同比增加超過1.68倍。
醫療服務板塊集體拉昇。中國衛生集團漲超22%；百濟神州漲超11%；科濟藥業-B漲超10%；藥明巨諾-B漲超9%；信達生物、康方生物-B等多股漲超8%；智雲健康漲超6%；清晰醫療漲超5%；中國生物科技服務漲超4%；諾輝健康-B漲超3%。中國衛生集團特別股東大會通過“10 合 1”股份合併；百濟神州BTK百悅澤上半年全球收入2.331億美元，在美銷售額同比增長5倍；藥明巨諾－Ｂ漲11.13%；信達生物曾續漲11%，溢價發新股引資賽諾菲；交銀推薦買入康方生物及榮昌生物(09995）持續看好中國創新藥研發；中國生物科技服務發盈喜，預期中期取得公司擁有人應佔溢利淨額不少於6500萬港元，同比增加超過1.68倍。
品牌零售板塊走弱。易還財務投資跌超7%；賓仕國際跌超6%；高鑫零售跌超3%；利特米跌超1%。
石油天然氣板塊走弱。能源國際投資跌超9%；華榮能源跌超8%；絲路能源跌超6%；中國秦發、冠軍科技集團等多股跌超4%。能源國際投資擬“10合1”並股。
電腦與外圍設備板塊走弱。豆盟科技跌超5%；中國育兒網絡、羚邦集團、知乎-W等多股跌超4%；太平洋網絡跌超3%。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
